Jardiance vs Tresiba: Switching Between Empagliflozin and Insulin Degludec

How Jardiance and Tresiba Work Differently

These two drugs occupy opposite ends of the glucose-lowering toolbox. Understanding why matters before discussing any switch.

Jardiance (empagliflozin) blocks the sodium-glucose co-transporter 2 in the proximal renal tubule, causing the kidneys to excrete roughly 70 grams of glucose per day into the urine 1. This mechanism operates independently of insulin secretion. Because it doesn't stimulate beta cells, hypoglycemia risk stays low when Jardiance is used without sulfonylureas or insulin.

Tresiba (insulin degludec) takes the opposite approach. It supplies exogenous basal insulin through a multi-hexamer depot that forms after subcutaneous injection, producing an ultra-flat pharmacokinetic profile lasting beyond 42 hours 2. That extended duration reduces day-to-day glucose variability compared with older basal insulins. The trade-off: exogenous insulin carries inherent hypoglycemia risk, and dosing requires titration.

A patient on Jardiance alone may eventually need Tresiba if beta-cell function declines. A patient on Tresiba alone may benefit from adding Jardiance for cardiovascular or kidney protection. These are not competing drugs. They address different physiological deficits.

Cardiovascular Trial Evidence: EMPA-REG OUTCOME vs DEVOTE

The strongest argument for choosing one of these medications often comes down to cardiovascular data. Both drugs have dedicated outcomes trials, but they tested very different hypotheses.

EMPA-REG OUTCOME enrolled 7,020 patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Over a median follow-up of 3.1 years, empagliflozin (pooled 10 mg and 25 mg doses) reduced the primary composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% (HR 0.86 to 95% CI 0.74 to 0.99). The cardiovascular death reduction was striking: 38% (HR 0.62 to 95% CI 0.49 to 0.77) 1. All-cause mortality fell by 32%. Dr. Bernard Zinman, the trial's lead investigator, noted that "the magnitude of the reduction in cardiovascular death was unexpected and not explained by modest differences in glycemic control" 1.

DEVOTE randomized 7,637 patients with type 2 diabetes at high cardiovascular risk to insulin degludec versus insulin glargine U100. The trial demonstrated non-inferiority for the three-point MACE composite (HR 0.91 to 95% CI 0.78 to 1.06) 2. Degludec did not reduce cardiovascular events below the glargine comparator, but it did produce 40% fewer episodes of severe nocturnal hypoglycemia (rate ratio 0.60, P<0.001) 2.

These trials answer different questions. EMPA-REG asked whether empagliflozin reduces cardiovascular events versus placebo on top of standard care. DEVOTE asked whether degludec is at least as safe as glargine. No head-to-head trial has compared empagliflozin directly against insulin degludec for cardiovascular outcomes.

When Switching from Jardiance to Tresiba Makes Clinical Sense

The most common reason to add or switch to basal insulin is progressive beta-cell failure. This is not a failure of the patient or of Jardiance.

Type 2 diabetes is a progressive disease. The UK Prospective Diabetes Study showed that approximately 50% of patients on monotherapy needed additional agents within three years 3. When A1C remains above target (typically 7.0% per ADA Standards of Care) despite maximum oral therapy, the 2024 ADA/EASD consensus recommends considering injectable therapy, including basal insulin 4.

Specific indicators for adding Tresiba to a regimen that includes Jardiance:

• Fasting glucose consistently above 180 mg/dL despite dual or triple oral therapy
• A1C above 9.0% with symptoms of hyperglycemia (polyuria, polydipsia, unintentional weight loss)
• Evidence of significant insulin deficiency (low fasting C-peptide)

The typical starting dose for Tresiba in insulin-naive patients is 10 units once daily, titrated by 2 units every 3 to 4 days targeting a fasting glucose of 80 to 130 mg/dL 5. When adding Tresiba, Jardiance is usually continued. The ADA explicitly recommends maintaining SGLT2 inhibitor therapy alongside insulin for patients with established cardiovascular disease or high cardiovascular risk 4.

When Adding Jardiance to an Existing Tresiba Regimen Is Preferred

For patients already on Tresiba, adding Jardiance can reduce A1C, body weight, blood pressure, and cardiovascular risk simultaneously.

The EMPA-REG OUTCOME population included patients on background insulin therapy (48% of participants), and the cardiovascular benefit was consistent in this subgroup 1. This means the 38% CV death reduction applied even when empagliflozin was layered on top of insulin.

Practical benefits of adding Jardiance to Tresiba include a typical insulin dose reduction of 10 to 20%, which can offset weight gain from insulin and reduce hypoglycemia risk. A 2019 meta-analysis in Diabetes, Obesity and Metabolism showed that SGLT2 inhibitors added to insulin reduced total daily insulin dose by a mean of 8.8 units while lowering A1C by an additional 0.56 percentage points 6. Blood pressure drops by approximately 4 mmHg systolic with empagliflozin, an effect unrelated to glucose lowering 1.

When Jardiance is added to Tresiba, clinicians should consider a proactive 10 to 20% reduction in insulin dose to prevent hypoglycemia, particularly if the patient's fasting glucose is already near target.

Safety Considerations When Combining or Switching

Neither drug is free of adverse effects. Knowing what to monitor during a transition matters.

Jardiance's SGLT2 mechanism produces glycosuria, which increases the risk of genital mycotic infections (yeast infections) in roughly 6 to 8% of women and 3 to 4% of men 7. Volume depletion can occur, particularly in elderly patients on diuretics. Rare but serious risks include diabetic ketoacidosis (DKA), which can present with near-normal blood glucose levels (euglycemic DKA). The FDA issued a safety communication about SGLT2 inhibitors and DKA in 2015 8.

Tresiba's primary risk is hypoglycemia. While DEVOTE showed 40% fewer severe nocturnal events compared with glargine U100, the overall rate of severe hypoglycemia was 4.9% per year in the degludec group 2. Tresiba's 42-hour-plus half-life means dose changes take 3 to 4 days to reach full effect. Patients and clinicians must resist the urge to titrate too quickly.

Key monitoring during combination use or switching:

• Check fasting glucose daily during the first two weeks of any change
• Monitor renal function (eGFR) at baseline and within one month; Jardiance should not be initiated if eGFR is below 20 mL/min/1.73 m² per updated FDA labeling 8
• Educate patients about DKA symptoms if on Jardiance, especially during illness, surgery, or reduced carbohydrate intake
• Assess for genital mycotic infection symptoms within the first 3 months of starting Jardiance

Weight, Cost, and Quality-of-Life Differences

Beyond glucose numbers, practical differences between these medications shape daily life for patients.

Jardiance produces consistent weight loss. Pooled data from phase III trials showed mean reductions of 1.8 kg (10 mg) and 2.5 kg (25 mg) versus placebo over 24 weeks 7. This weight effect is caloric, driven by urinary glucose excretion of roughly 200 to 300 kcal per day.

Tresiba is weight-neutral to slightly weight-positive. In DEVOTE, mean weight gain with degludec was comparable to glargine at approximately 1 to 2 kg over two years 2. For patients concerned about weight, combining Tresiba with Jardiance can partially offset insulin-associated weight gain.

Cost remains a barrier for both drugs. The wholesale acquisition cost (WAC) for Jardiance 25 mg is approximately $550 to $600 per month. Tresiba's WAC varies by dose but starts around $400 to $500 per month for lower doses. Manufacturer savings cards can reduce out-of-pocket cost to as low as $10 to $25 per month for commercially insured patients. Medicare Part D patients face different cost-sharing structures under the Inflation Reduction Act's $2,000 annual out-of-pocket cap, which took effect in 2025.

Administration route affects adherence. Oral once-daily dosing with Jardiance eliminates needle anxiety. Tresiba's FlexTouch pen and flexible dosing window (up to 8 hours of daily timing variation without compromising efficacy) reduce the burden of injectable therapy compared with older insulins that demand rigid timing.

ADA 2024 Positioning: Where Each Drug Fits in the Algorithm

The 2024 ADA Standards of Care place SGLT2 inhibitors and basal insulin in distinct positions within the treatment algorithm for type 2 diabetes.

For patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, the ADA recommends an SGLT2 inhibitor (or GLP-1 receptor agonist) regardless of A1C, as first-line add-on therapy to metformin or even as initial therapy 4. This recommendation is driven by organ-protection data, not glucose lowering alone. Jardiance's indication for reducing cardiovascular death in T2D with CVD and its approval for heart failure (regardless of diabetes status) make it a preferred agent in these populations.

Basal insulin, including Tresiba, enters the algorithm when glycemic targets are not met despite optimized oral and injectable non-insulin therapies, or when patients present with significant hyperglycemia (A1C above 10% or glucose above 300 mg/dL) and symptoms suggesting insulin deficiency 4. The ADA does not recommend discontinuing SGLT2 inhibitors when insulin is added, provided the patient has appropriate indications for both.

Dr. Robert Gabbay, ADA Chief Scientific and Medical Officer, stated in the 2024 Standards revision: "The treatment of type 2 diabetes should be individualized, with cardio-renal protection prioritized in those with or at high risk for these complications" 4.

Renal Considerations for Both Drugs

Kidney function determines whether Jardiance can be used and how Tresiba should be dosed.

Jardiance has expanded renal indications beyond its original glucose-lowering approval. The EMPA-KIDNEY trial (N=6,609) demonstrated a 28% reduction in the composite of kidney disease progression or cardiovascular death in patients with CKD, with or without diabetes 9. The FDA now permits initiation of empagliflozin at eGFR as low as 20 mL/min/1.73 m² for cardiorenal protection, though glucose-lowering efficacy diminishes below eGFR 45 9.

Tresiba requires no dose adjustment for renal impairment, since insulin is cleared by receptor-mediated endocytosis rather than renal filtration 5. However, patients with declining kidney function often experience reduced insulin clearance and may need dose reductions to prevent hypoglycemia. Close glucose monitoring is warranted during CKD progression.

For a patient with eGFR between 20 and 45, Jardiance can still be initiated for cardiorenal protection, but glucose-lowering will be modest. Tresiba remains the primary glucose-lowering tool in this eGFR range.